Skip to main content

Intuitive Surgical (ISRG) Stock Price & Market Analysis

ISRG · NASDAQ · Medical - Instruments & Supplies

Market closedLatest available session print

$449.53

▼ -$0.5100(-0.11%)4:00 PM ET - vs previous close

Quote as of Nov 11, 2026, 4:00 PM EST

Regular-session close · Nov 11, 2026, 4:00 PM EST.

Last session81%
$443.24L Nov 11 '26$450.99H Nov 11 '26
52-week range44%
$328.57L Jul 23 '26$603.88H Jan 7 '26
Long-term rangesAvailable history
Available history(2000-11-13)73%
$0.6667L Apr 3 '01$616.00H Jan 23 '25

Historical range: 2000-11-13–2026-11-11. Earlier trading may not be included.

Loading price chart…

Data dates

PriceAt closeLast traded

FundamentalsLast checked

AnalystLast checked

NewsLatest item

What matters next

Next important events

  1. Jan 21, 2027Next earnings (est.)Estimated

Countdown

70 days out

Reported fundamentals

ISRG financial overview

Annual revenue

USD 10.06B

Sales for the fiscal year ended Dec 31, 2025. This is not trailing twelve-month revenue.

Revenue change

+20.5%

Change versus the fiscal year ended Dec 31, 2024.

Net profit margin

28.4%

Net income divided by revenue for the fiscal year ended Dec 31, 2025. This is not the trailing margin.

These reported results describe the business’s recent scale and profitability. Compare cash generation and valuation before forming an investment view; historical growth is not a forecast.

Company · ProfileAbout Intuitive Surgical (ISRG)Sector, leadership, and how Intuitive Surgical earns its revenue.

Intuitive Surgical

NASDAQ · ISRG · US

Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.

Company overview as of Nov 11, 2026.

Sector
Healthcare
Industry
Medical - Instruments & Supplies
Headquarters
Sunnyvale, CA, United States
Country
US
Employees
17,021
CEO
Mr. David J. Rosa
Exchange
NASDAQ
Business model & operating resultsExplore business exposure, reported operating measures and the figures behind growth and profitability claims.

Company website ↗

Narrative versus numbers

Demand is expanding

Supporting observation: 21.7%

Year-over-year growth in the latest quarter. This differs from the fiscal-year revenue change shown above. · Source timestamp: Sep 30, 2026

Growth produces accounting profit

Supporting observation: 25.5%

Net margin; the source did not supply a reporting period. Do not compare this reading with the quarterly or fiscal-year figures above. A positive margin does not establish cash generation. · Source timestamp: Nov 11, 2026, 11:02 PM EST

The business generates cash after investment

Supporting observation: USD 1.11B

Latest free cash flow from the statement feed. It is not a forecast and may cover a different period from the fiscal-year figures above. · Source timestamp: Sep 30, 2026

These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.

Operating measures

Revenue
$3.05Bquarter ended Sep 30, 2026
Gross margin
68.4%quarter ended Sep 30, 2026
Operating margin
19.4%quarter ended Sep 30, 2026
EPS
$1.49quarter ended Sep 30, 2026
Capital expenditure
$113.10Mquarter ended Sep 30, 2026
Free cash flow
$1.11Bquarter ended Sep 30, 2026
Free cash flow margin
36.4%quarter ended Sep 30, 2026
Operating cash / net income
2.34×quarter ended Sep 30, 2026
Revenue growth year over year
21.7%quarter ended Sep 30, 2026
Competitors & comparisonsCompare industry peers, reporting periods and related funds. Business mix and valuation bases may differ.
Valuation & fund comparisonsExplore dated peer valuations, growth comparisons and related funds.

Governance & sustainability

Find proxy statements and annual reports

Data sources: Financial Modeling Prep · Finnhub · SEC Companyfacts · Yahoo Finance

Market data is for information only and is not trading advice. Prices and fundamentals may be delayed, reflect an earlier observation, be incomplete, or be revised. Read the data methodology or the full disclaimer.
Research tools
Market closed

Regular hours: 9:30 AM–4:00 PM America/New_York

Next open: 2026-11-12 · 9:30 AM America/New_York

Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.